Depression, bone loss, and other conditions linked to low testosterone

Low testosterone is linked to depressed mood, reduced bone density, muscle loss, and several other health problems, especially in men who remain symptomatic with total testosterone below 350 ng/dL or free testosterone below 100 pg/mL. Male hypogonadism is a clinical syndrome, not a lab number, so these links matter only when persistent symptoms are paired with biochemical evidence. This guide covers the relationship, how it works, conditions linked to it, symptoms and signals, and what to do about it.

Key takeaways

• Male hypogonadism requires both persistent symptoms and biochemical deficiency, and Veedma uses decision thresholds of 350 ng/dL for total testosterone and 100 pg/mL for free testosterone on a morning draw between 07:00 and 11:00, with LH, FSH, and estradiol included in the core workup.
• A meta analysis of 27 randomized trials involving 1,890 men found that testosterone therapy can improve mild depressive symptoms, but it is not an established treatment for most men with clinical depressive disorders.
• Severe hypogonadism, defined here as total testosterone below 3.5 nmol/L, is frequently associated with bone loss and osteoporosis, while fracture reduction from TRT remains unproven.
• TRT increases lean mass and reduces fat mass, but functional gains in older men are modest, so resistance training remains important for sarcopenia prevention.
• The TRAVERSE trial followed 5,246 men for a mean of 33 months and found TRT noninferior to placebo for major cardiovascular events, but atrial fibrillation occurred in 3.5 percent vs 2.4 percent.
• Klinefelter syndrome affects about 1 in 500 to 1,000 male births, yet fewer than half of affected men are ever diagnosed.

The relationship

The relationship between low testosterone and depressed mood is clinically important, but a direct cause and effect link has not been conclusively proved.^{[1] [2]}

Hypogonadism means a clinical syndrome of testosterone deficiency that requires persistent symptoms plus confirming laboratory evidence. A low number alone is not a diagnosis, and mood symptoms alone are not enough either. Before concluding that low testosterone and depression are connected in a specific man, testing should be done on a morning blood draw between 07:00 and 11:00, with total testosterone, direct free testosterone by equilibrium dialysis with LC-MS/MS, estradiol, LH, and FSH as the core workup, with prolactin, TSH, and vitamin D added when clinically indicated. For the diagnostic framework, see the clinical definition of low testosterone and the complete low testosterone testing guide.

That classification step matters because treatment differs by mechanism. High LH with low testosterone points to primary hypogonadism, which reflects testicular failure and usually requires TRT. Low or normal LH with low testosterone points to secondary or functional hypogonadism, where the testes may still respond. At Veedma, that is why LH and FSH are always ordered alongside testosterone, free testosterone is measured directly rather than estimated, and men with secondary or functional hypogonadism and LH below 8 mIU/mL are generally considered for Enclomiphene first, while testosterone cypionate is reserved for men who truly need TRT.

What treatment can and cannot do for mood

Testosterone therapy can improve mild depressive symptoms in hypogonadal men, but it should not be framed as a stand alone treatment for major depressive disorders. According to a 2019 JAMA Psychiatry meta analysis, the benefit was most evident in men with milder depressive symptoms and confirmed testosterone deficiency. The Testosterone Trials also found mood improvement, but the effect size was modest rather than transformative. In practice, that means hormonal treatment may help when low mood travels with low libido, fatigue, and other features of hypogonadism, but severe depression still requires conventional psychiatric care, psychotherapy, or both.

How it works

How it works at the skeletal level is that sex steroid deficiency shifts bone remodeling toward loss, which is why severe hypogonadism, defined here as total testosterone below 3.5 nmol/L, is frequently associated with bone loss and osteoporosis regardless of age.^[4]

Bone mineral density means the amount of mineral packed into bone. Osteopenia means bone density is below normal. Osteoporosis means bone fragility is high enough to raise fracture risk. The relationship between testosterone and bone loss is not equally strong across the whole spectrum of deficiency. Mild hypogonadism has a weaker association with osteopenia and osteoporosis. Severe deficiency is different. A 2006 Journal of Clinical Endocrinology and Metabolism study found that sex steroid deficiency in older men tracked with both osteoporosis and more rapid bone loss, supporting the clinical observation that profound testosterone deficiency is a genuine skeletal risk, not merely a laboratory curiosity.^[4]

This matters because men often notice sexual or energy changes long before they think about bone health. Yet testosterone deficiency can quietly affect the skeleton for years. In a symptomatic man with very low testosterone, bone loss should be considered part of the disease burden, especially if he also has muscle loss or reduced physical activity.

What TRT does and does not change for bone

TRT increases bone mineral density, especially at the lumbar spine, but fracture reduction has not been proved.^[3]

According to the Testosterone Trials bone substudy, testosterone treatment increased volumetric bone density and estimated bone strength, with particularly clear gains in the spine. That fits the broader literature, where reviews and meta analyses consistently show a favorable effect on bone mineral density. What the evidence has not yet shown is a clear reduction in fractures. That distinction is clinically important. Bone density is a surrogate marker. Fracture prevention is the hard outcome that matters most.

For that reason, TRT should be viewed as adjunctive rather than primary bone treatment when fracture risk is already high. Men at high skeletal risk still need standard osteoporosis management, including anti resorptive therapy when indicated. Testosterone can support the hormonal part of the problem, but it does not replace dedicated bone treatment.

Symptoms and signals

Symptoms and signals of clinically important testosterone deficiency often include lower libido, fatigue, loss of lean mass, rising fat mass, and reduced physical capacity, making muscle related change one of the most practical clues in symptomatic men.^{[2] [5]}

Testosterone is anabolic, which means it supports tissue building. In adult men, one of its best established actions is stimulation of muscle protein synthesis and maintenance of lean body mass. When testosterone falls, the expected pattern is less muscle and more fat, even before obvious frailty appears. A 2010 randomized trial in mobility limited older men found that testosterone improved body composition, and the larger Testosterone Trials later showed that functional measures can improve as well, although only modestly.^{[2] [5]}

This is one reason low testosterone related conditions often overlap. A man with low testosterone and depression may also report reduced physical confidence, slower walking, or difficulty maintaining muscle despite regular exercise. Those changes are not simply cosmetic. Loss of lean mass can feed inactivity, worsen metabolic health, and increase fall risk over time.

Mass gains are not the same as function gains

TRT reliably increases muscle mass and reduces fat mass, but meaningful functional improvement in older men is less consistent. According to the Testosterone Trials, walking distance improved only modestly. That is why treatment expectations should stay realistic. More muscle on a scan or better body composition on paper does not automatically translate into major gains in grip strength, stair climbing, or athletic performance, particularly in older men with sarcopenia. Sarcopenia means age related loss of muscle mass and function.

The best practical strategy is combined therapy. When hypogonadism is documented, TRT can address the hormonal driver of testosterone and muscle loss. Strength training still provides the most direct stimulus for functional adaptation. In older men, especially, the combination of correcting true hormonal deficiency and doing progressive resistance exercise remains the best supported approach for preserving mobility and reducing frailty.

What low testosterone related prostate and urinary concerns actually show

Current evidence does not show that testosterone therapy worsens routine urinary symptoms or increases prostate cancer risk in hypogonadal men.^{[6] [7] [8]}

This area is where old assumptions still shape patient fears. LUTS means lower urinary tract symptoms such as frequency, urgency, nocturia, and weak stream. BPH means benign prostatic hyperplasia, or noncancerous enlargement of the prostate. For years, many men were told that TRT would inevitably worsen urinary symptoms or that testosterone and prostate cancer were tightly linked in a simple dose response way. Recent evidence does not support either claim.

LUTS and BPH

Meta analyses show no significant difference in LUTS between testosterone treated and placebo groups, and storage symptoms may even improve.^[6]

A 2016 European Urology systematic review found no meaningful worsening of urinary symptoms with TRT. Some men actually reported improvement in storage symptoms, which include urgency and frequency. The main caution is that evidence is limited in men with severe symptoms, because those patients are usually excluded from trials. IPSS means International Prostate Symptom Score, a questionnaire used to grade urinary symptom severity. When IPSS is above 19, evidence is thinner, so treatment should be individualized rather than assumed safe by default.

Prostate cancer

Recent literature and randomized trials do not support the old claim that testosterone therapy “feeds” prostate cancer in hypogonadal men.^{[7] [8]}

According to a 2014 meta analysis in Prostate Cancer and Prostatic Diseases, TRT did not increase PSA or prostate cancer risk across randomized trials. The TRAVERSE trial then provided the most definitive large scale safety data to date, following 5,246 men for a mean of 33 months without showing a signal for increased prostate cancer incidence. PSA means prostate specific antigen, a prostate derived blood marker used for monitoring, not a cancer diagnosis by itself.

There is one nuance worth keeping. Some observational work has suggested that men with very low free testosterone may present with higher grade prostate cancer more often, although the association has been inconsistent and not statistically robust across studies. That observation does not mean TRT causes cancer. It means the relationship between androgen status and prostate biology is more complex than the older “more testosterone, more cancer” model suggested. Active or advanced prostate cancer remains an absolute contraindication to TRT, but the blanket fear that testosterone therapy itself creates prostate cancer is not supported by current evidence.

What TRT cardiovascular safety data really show

The best current evidence shows that TRT was noninferior to placebo for major cardiovascular events in 5,246 men followed for a mean of 33 months.^[8]

MACE means major adverse cardiovascular events, usually the composite of heart attack, stroke, or cardiovascular death. According to the 2023 New England Journal of Medicine TRAVERSE trial, TRT did not increase that composite outcome in men with documented hypogonadism who already had cardiovascular disease or were at high cardiovascular risk. That finding settled the long running question of whether TRT routinely raises heart attack risk when used appropriately in hypogonadal men.

Reassuring is not the same as risk free. In the same trial, atrial fibrillation occurred more often with TRT, 3.5 percent versus 2.4 percent, and there were also higher rates of pulmonary embolism and acute kidney injury. The accompanying TRAVERSE Diabetes analysis pointed in the same safety direction within men who also had diabetes or prediabetes. The practical takeaway is that TRT cardiovascular safety is acceptable in properly selected men, but prior arrhythmia, venous thromboembolism, or kidney disease still deserves individualized review.

Sleep apnea and erythrocytosis

Erythrocytosis is the most common adverse effect of TRT, while current evidence does not show a persistent onset or worsening effect on sleep apnea.^{[9] [10]}

Erythrocytosis means an abnormally high red blood cell concentration, usually tracked by hematocrit. Testosterone normally stimulates erythropoiesis, which means red blood cell production. Hematocrit elevations usually emerge between 3 and 12 months after starting therapy. In clinical practice, a hematocrit above 54 percent is the usual threshold for dose reduction, formulation change, or venesection, which means therapeutic blood removal, because risk appears to rise as hematocrit increases even though an exact safe cutoff is not firmly established. This problem is more common with injectable formulations than with topical therapy. That distinction matters because TRAVERSE used gel based TRT, so its reassuring safety profile should not be assumed to erase the higher hematocrit risk seen with injections.^[10]

Sleep apnea is often misunderstood in the same way. A 2012 randomized trial in obese men with severe obstructive sleep apnea found a temporary reduction in oxygen saturation at 7 weeks, but the effect had normalized by 18 weeks, and the broader evidence does not show that TRT causes persistent onset or worsening of sleep apnea. In men whose obstructive sleep apnea is already being treated, TRT may improve hypogonadal symptoms, but it is not a treatment for sleep apnea itself. Sleep apnea is therefore not considered a contraindication, although monitoring remains sensible in men with severe disease.

At Veedma, safety monitoring is built around the same principle as diagnosis. Men are assessed with more than 40 biomarkers twice per year, including CBC for hematocrit, comprehensive metabolic panel, estradiol, LH, FSH, direct free testosterone, and PSA in men over 40, while lipid panels are added when clinically indicated. Protocol adjustments are based on response and adverse effects rather than fixed dosing.

Conditions linked to it

Among the conditions linked to it are lifelong genetic disorders, and Klinefelter syndrome is the most common example.^{[11] [12]}

Klinefelter syndrome is a chromosomal condition, usually 47,XXY, that causes primary testicular failure. A 2003 national registry study estimated a prevalence of roughly 1 in 500 to 1,000 male births, and fewer than half of affected men are ever diagnosed. That makes it one of the most common and most frequently missed male genetic endocrine disorders.^[11]

Klinefelter syndrome

Klinefelter syndrome usually presents as primary hypogonadism, infertility, and sometimes cognitive or language related difficulties. Because the testes are intrinsically impaired, these men are not candidates for a stimulation only strategy if testosterone production is already failing. That is the key distinction between lifelong genetic primary hypogonadism and reversible functional secondary hypogonadism. For the classification framework, see primary vs secondary hypogonadism.

The management implications are long term. Genetic primary hypogonadism generally requires ongoing hormonal management, fertility counseling, and broader monitoring than acquired low testosterone that developed later in life. In other words, genetic conditions are low testosterone related conditions, but they are not managed the same way as depression associated with low T, testosterone and bone loss, or testosterone and muscle loss in adult onset disease.

Other genetic causes

Myotonic dystrophy, disorders of sex development, and Kennedy disease are less common genetic causes of androgen deficiency or androgen resistance. Androgen resistance means the body does not respond normally to testosterone even when hormone levels are present. These disorders can produce lifelong symptoms, infertility, or both, and they require a different management mindset than acquired hypogonadism caused by age, illness, or medication.

The diagnostic lesson is the same one that runs through every low testosterone evaluation. Morning testosterone values need context. Free testosterone should be measured directly, and LH and FSH must be included so the clinician can tell whether the problem starts in the testes or higher in the signaling axis. Veedma uses that framework whether it is ordering a full workup or analyzing existing outside labs, including comprehensive panels that men may already have from services such as Function Health.

Myth vs fact

Myth: Testosterone is a treatment for major depression

Fact: Testosterone therapy can improve mild depressive symptoms in hypogonadal men, but evidence does not support it as an effective primary treatment for most men with clinical depressive disorders.^[1]

Myth: TRT causes prostate cancer

Fact: Meta analyses and the TRAVERSE trial do not show an increased prostate cancer risk in hypogonadal men receiving TRT, although active or advanced prostate cancer remains an absolute contraindication.^{[7] [8]}

Myth: If TRT improves bone density, it must prevent fractures

Fact: TRT increases bone mineral density, especially in the lumbar spine, but fracture reduction has not been demonstrated, so men at high fracture risk still need standard osteoporosis treatment.^[3]

Myth: TRT always worsens BPH and urinary symptoms

Fact: A systematic review and meta analysis found no significant worsening of LUTS with TRT, and some storage symptoms may improve. Evidence is simply thinner in men with severe symptoms, usually defined by an IPSS above 19.^[6]

What to do about it

What to do about it starts with confirming persistent symptoms and biochemical deficiency on properly timed morning testing, including total testosterone, direct free testosterone, estradiol, LH, and FSH. Once true hypogonadism is established, treatment should match the mechanism, with TRT reserved for men who need replacement and alternatives considered when secondary or functional hypogonadism may still be reversible. Depression, osteoporosis, urinary problems, and cardiovascular risk still need their own evidence based care plans even when low testosterone is part of the picture. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

References

1. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA psychiatry. 2019;76:31-40. PMID: 30427999
2. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. The New England journal of medicine. 2016;374:611-24. PMID: 26886521
3. Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. The Journal of clinical endocrinology and metabolism. 2006;91:2011-6. PMID: 16522694
4. Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. The Journal of clinical endocrinology and metabolism. 2006;91:3908-15. PMID: 16849417
5. Basaria S, Coviello AD, Travison TG, et al. Adverse Events Associated with Testosterone Administration. The New England journal of medicine. 2010;363:109-22. PMID: 20592293
6. Kohn TP, Mata DA, Ramasamy R, et al. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. European urology. 2016;69:1083-90. PMID: 26874809
7. Cui Y, Zong H, Yan H, et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate cancer and prostatic diseases. 2014;17:132-43. PMID: 24445948
8. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England journal of medicine. 2023;389:107-117. PMID: 37326322
9. Hoyos CM, Killick R, Yee BJ, et al. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clinical endocrinology. 2012;77:599-607. PMID: 22512435
10. Pastuszak AW, Gomez LP, Scovell JM, et al. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sexual medicine. 2015;3:165-73. PMID: 26468380
11. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. The Journal of clinical endocrinology and metabolism. 2003;88:622-6. PMID: 12574191
12. Groth KA, Skakkebaek A, Høst C, et al. Clinical review: Klinefelter syndrome: a clinical update. The Journal of clinical endocrinology and metabolism. 2013;98:20-30. PMID: 23118429